Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arbaclofen Open-Label Extension in ASD
NCT01706523Phase 3Terminated
- Sponsor
- Seaside Therapeutics
- Start
- Nov 2011
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of arbaclofen in Autism Spectrum Disorder (ASD), sponsored by Seaside Therapeutics. Started Nov 2011; status: terminated.
02
Drugs
arbaclofen
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT01706523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01706523.